NCT07308496 (CONQUER) is a NA clinical trial of CT-FFR guided strategy in Coronary Artery Disease, sponsored by China National Center for Cardiovascular Diseases.

Who is sponsoring NCT07308496?

NCT07308496 is sponsored by China National Center for Cardiovascular Diseases.

What drugs are being tested in NCT07308496?

Interventions in NCT07308496: CT-FFR guided strategy, QFR guided strategy.

What condition does NCT07308496 study?

NCT07308496 studies Coronary Artery Disease.

Is NCT07308496 still recruiting?

NCT07308496 is currently not yet recruiting. Last updated 12 February 2026.

Last reviewed 2026-02-12 · How we verify

NCT07308496: CONQUER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Computed Tomography-derived Fractional Flow Reserve vs. Angiographic Quantitative Flow Ratio in Management of Patients With Coronary Artery Disease

Not yet recruiting NA Last updated 12 February 2026

What this trial tests

NA trial testing CT-FFR guided strategy in Coronary Artery Disease in 1,402 participants. Not yet recruiting.

Timeline

1 March 2026

Primary endpoint
1 July 2028

1 July 2028

Quick facts

Lead sponsor	China National Center for Cardiovascular Diseases
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	1,402
Start date	1 March 2026
Primary completion	1 July 2028
Estimated completion	1 July 2028

Drugs / interventions tested

CT-FFR guided strategy
QFR guided strategy

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →

Sponsor

China National Center for Cardiovascular Diseases — full company profile →

Who can join

18 and older, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center, randomized controlled trial to compare the clinical outcomes between CT-derived fractional flow reserve (CT-FFR) guided strategy and angiography-derived quantitative flow ratio (QFR) guided strategy among patients with coronary artery disease (CAD). Participants who have at least one coronary stenosis of 70%-90% (vessel diameter ≥2.5 mm) detected by coronary CT angiography will be enrolled and are randomly assigned in a 1:1 ratio to CT-FFR guided group or QFR guided group. In CT-FFR group, the decisions of invasive angiography and revascularization will be guided by CT-FFR. In QFR group, the decision of invasive angiography will be made as usual care, and revascularization will be guided by QFR. The primary endpoint is the 1-year incidence of major adverse cardiac events (MACEs), including death, myocardial infarction, and unplanned revascularization.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Other China National Center for Cardiovascular Diseases trials

Trials by the same sponsor.

NCT07514988 — Sirolimus-Coated vs Paclitaxel-Coated DCBs in ACS Treatment · NA · not yet recruiting
NCT07476456 — Skeletal Muscle Multi-omics Analysis and Risk Tailoring in Sudden Cardiac Death · not yet recruiting
NCT07302659 — Aortic No-Touch vs Partial Aortic Clamping in Off-Pump CABG · NA · recruiting
NCT07482683 — Predicting Post-Cardiac Surgery Acute Kidney Disease: A Machine Learning Approach · not yet recruiting
NCT06787430 — Effects of Nicorandil on Microvascular Dysfunction in Patients With STEMI Undergoing Primary PCI · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07308496 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by China National Center for Cardiovascular Diseases
Last refreshed: 12 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07308496.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing